Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / FID-007
Other

FID-007

Tracked across 1 events · 8 articles · First seen May 21, 2026 · Last active Jun 01, 2026

Sentiment
70
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 70
Tech
Fulgent FID-007 Phase 2 Results
Fulgent Genetics announced and presented updated interim data from its open-label, randomized Phase 2 study of FID-007 in combination with Cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at the…
Impact: FID-007 is the drug candidate developed by Fulgent Genetics that showed meaningful clinical activity and a favorable safety profile in combination with cetuximab for treating R/M HNSCC.
May 21, 2026 · 8 articles
Key Actions (2)
95 FID-007 demonstrated anticancer activityFulgent FID-007 Phase 2 Results
90 FID-007 exhibited favorable safetyFulgent FID-007 Phase 2 Results
NEWSDESK
Track FID-007 live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.